This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SNCA Seneca Biopharma (SNCA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Seneca Biopharma Stock (NASDAQ:SNCA) Get Seneca Biopharma alerts:Sign Up Key Stats Today's Range$1.86▼$2.0050-Day Range$1.39▼$10.2552-Week Range$0.50▼$2.67Volume1.84 million shsAverage Volume3.78 million shsMarket Capitalization$32.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. Read More Receive SNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seneca Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNCA Stock News HeadlinesLeading BioSciences Inc, Seneca Biopharma, Inc. - M&A Call TranscriptMarch 2, 2024 | gurufocus.comLeading BioSciences, Inc., Seneca Biopharma, Inc. - M&A Call TranscriptMarch 2, 2024 | gurufocus.comYour 10X AI demo is starting…Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investment of 17 million dollars. He is known for predicting the 2020 market crash with striking accuracy. Today he is hosting a free live demo of his newest AI-driven trading approach, showing how he analyzes market data without guesswork or speculation. | TradeSmith (Ad)Seneca Foods Corp Class ADecember 16, 2023 | morningstar.comMWest Seneca West Senior High SchoolApril 30, 2023 | usnews.comSeneca High SchoolApril 19, 2023 | usnews.com'This is a tragedy': Giraffe dies after getting caught in enclosure gate at New York zooFebruary 16, 2023 | usatoday.comSee More Headlines SNCA Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Seneca Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seneca Biopharma investors own include Matinas Biopharma (MTNB), Ocugen (OCGN), Tonix Pharmaceuticals (TNXP), Bionano Genomics (BNGO) and Artelo Biosciences (ARTL). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SNCA CIKN/A Webwww.senecabio.com Phone(301) 366-4960FaxN/AEmployees7Year Founded1996Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.35 million Net Margins-230.34% Pretax MarginN/A Return on Equity-122.20% Return on Assets-110.61% Debt Debt-to-Equity RatioN/A Current Ratio14.96 Quick Ratio14.96 Sales & Book Value Annual Sales$10 thousand Price / Sales3,234.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.41Miscellaneous Outstanding Shares17,296,000Free FloatN/AMarket Cap$32.34 million OptionableNot Optionable Beta1.83 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SNCA) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe world's #2 gold miner is running on fumes [it has to buy]Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.